
USA - NASDAQ:CGIX -
4.61
-0.11 (-2.33%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.98 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.92 | ||
| P/tB | N/A | ||
| EV/EBITDA | -4.95 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.7% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | -71.81% | ||
| PM (TTM) | -71.5% | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.59 | ||
| Quick Ratio | 0.59 | ||
| Altman-Z | -23.21 |
ChartMill assigns a fundamental rating of 2 / 10 to CGIX.
ChartMill assigns a valuation rating of 1 / 10 to Cancer Genetics Inc (CGIX). This can be considered as Overvalued.
Cancer Genetics Inc (CGIX) has a profitability rating of 1 / 10.
The financial health rating of Cancer Genetics Inc (CGIX) is 2 / 10.